Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x100px
Document › Details

Temedica GmbH. (8/2/23). "Press Release: Temedica and AbbVie Germany Are Launching Digital Companion for Patients with Chronic Inflammatory Bowel Diseases".

Region Region Germany
Organisations Organisation Temedica GmbH
  Organisation 2 AbbVie Deutschland GmbH & Co. KG
  Group AbbVie (Group)
Products Product Tami digital patient companion app (Temedica / AbbVie)
  Product 2 Permea health data analytics platform
Index term Index term AbbVie–Temedica: digital patient companion app, 202308 collab launch of companion app Tami for patients with chronic IBD in Germany
Persons Person Seibert, Gloria S. (Temedica 202001 Managing Director + Co-Founder)
  Person 2 Seidel, Tino (AbbVie 202308 Director of Patient Engagement at AbbVie Germany)

> The patient companion app is available to all patients aged 18 and above suffering from chronic inflammatory bowel diseases (IBD) in Germany.

> Approximately 400,000 Germans are affected by chronic inflammatory bowel diseases.

> Integration of real-world evidence allows for individualized guidance and support of patients throughout their entire patient journey.

Temedica, a Munich-based health insights company, announces the launch of their digital patient companion app "Tami". The app was developed in collaboration with AbbVie Germany and is targeting the approximately 400,000 people in Germany suffering from chronic inflammatory bowel diseases (IBD). Tami is designed to help patients better manage their daily lives and provides them with personalized insights into their respective disease progression. The app offers a variety of different features, including the functionality to track individual symptoms and long-term disease course, as well as to identify potential influencing factors.

By connecting Temedica's real-world evidence platform "Permea" with the Tami app, Tami will be continuously enriched with valuable insights that arise from the linkage of relevant health-related real-world data. The collection and processing of this data fully comply with GDPR. Through Tami, patients gain direct access to relevant information about their individual disease course, possible influencing factors, and therapy-supporting measures. The data collected by Tami and Permea and the resulting scientific findings will also significantly contribute to gaining a comprehensive understanding of the care reality of IBD patients in Germany.

Gloria Seibert
Founder & Chief Executive Officer at Temedica

“Together with AbbVie, we have combined our strengths and expertise to develop the best possible digital solution for patients with chronic inflammatory bowel diseases. Patients often confront a multitude of different symptoms that can represent a significant burden in everyday life. With the Tami app and insights from our real-world evidence platform "Permea", we contribute to easing the everyday life of those affected and provide them with digital support according to their personal needs and disease progression.“

Tino Seidel
Director of Patient Engagement at AbbVie Germany

“As a healthcare company, we strive to develop innovative solutions that make a real difference in people's lives. Collaborating with Temedica and using novel insights from their real-world evidence platform "Permea" is an important step in this direction for us. By integrating valuable insights into the Tami app, we enable IBD patients to receive personalized support and access to relevant knowledge to improve their quality of life.”

Temedica and AbbVie Germany work according to the most modern medical and technological standards. To ensure that Tami meets the needs of patients and provides real value, Temedica and AbbVie Germany are consistently developing it further with the active participation of patients. The app is available free of charge.

About Temedica GmbH

Temedica is a health insights company based in Munich. Since 2016, it operates Europe's leading ecosystem for real-world insights in the healthcare sector. Temedica's mission is to enable personalized and individualized medicine, thereby focusing on patients and their individual needs. The company achieves this by linking health-related data from various sources, which are processed into valuable insights in compliance with the GDPR.

Temedica is backed by a consortium of renowned investors with many years of experience in the biopharmaceutical industry, including the founding investors of BioNTech. For further information, please visit

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

For further information and media inquiries, please contact:

Temedica GmbH
Anna Hauner
Corporate Communications
Phone: +49 (0) 175 4310301

AbbVie Deutschland GmbH & Co. KG
Kathrin Kuntz
Senior Brand Communication Manager
Phone: +49 173 591 123 3

Record changed: 2024-01-20


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Temedica GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top